Related  
Partner
Projects & Publications

Precision Medicine and Economics Projects and Publications from GEECS Members

Oncology Outcomes

Oncology Outcomes (O2), a highly experienced resource group dedicated to real-world evidence data generation and integration. Through this collaboration, Roche and O2 will work together to increase RWD acceptability and accessibility across the Canadian ecosystem.

Genesolve

The GeneSolve Study examines the value of genomic sequencing for diagnosing childhood rare diseases. Through a cross-institutional collaboration with Oxford University, PACER is developing new ways to address the high levels of uncertainty introduced by multi-omics technologies. This multi-country approach to economic analyses will support the timely and appropriate adoption of genomics for better diagnosing and treating children with rare diseases across jurisdictions.

TRANSPERS Center

The Center for Translational and Policy Research on Precision Medicine (TRANSPERS) is the premier research organization for developing evidence-based information about the use of precision medicine.

PAVE

Producing an Arthritis Value-Framework with Economic Evidence (PAVE), will explore health-care system costs and impacts on families including financial, education, employment, productivity, well-being and quality of life

Related Publications

  • Smit AK, Allen M, Beswick B, Butow P, Dawkins H, Dobbinson SJ, Dunlop KL, Espinoza D, Fenton G, Kanetsky PA, Keogh L, Kimlin MG, Kirk J, Law MH, Lo S, Low C, Mann GJ, Reyes-Marcelino G, Morton RL, Newson AJ, Savard J, Trevena L, Wordsworth S, Cust AE. Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial. Genet Med. 2021 Dec;23(12):2394-2403. Epub 2021 Aug 12. PMID: 34385669; PMCID: PMC8629758.

  • Smith HS, Morain SR, Robinson JO, Canfield I, Malek J, Rubanovich CK, Bloss CS, Ackerman SL, Biesecker B, Brothers KB, Goytia CN, Horowitz CR, Knight SJ, Koenig B, Kraft SA, Outram S, Rini C, Shipman KJ, Waltz M, Wilfond B, McGuire AL. Perceived Utility of Genomic Sequencing: Qualitative Analysis and Synthesis of a Conceptual Model to Inform Patient-Centered Instrument Development. Patient. 2022 May;15(3):317-328. Epub 2021 Oct 18. PMID: 34658003; PMCID: PMC9013723.

  • Shickh S, Oldfield LE, Clausen M, Mighton C, Sebastian A, Calvo A, Baxter NN, Dawson L, Penney LS, Foulkes W, Basik M, Sun S, Schrader KA, Regier DA, Karsan A, Pollett A, Pugh TJ, Kim RH, Bombard Y; CHARM Consortium. "Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management. Oncologist. 2022 May 6;27(5):e393-e401. PMID: 35385106; PMCID: PMC9075003.

  • Thom H, Leahy J, Jansen JP. Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias. Med Decis Making. 2022 May 7:272989X221097081.  Epub ahead of print. PMID: 35531938.

  • Kunst N, Stout NK, O'Brien G, Christensen KD, McMahon PM, Wu AC, Diller LR, Yeh JM. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. J Natl Cancer Inst. 2022 May 9;114(5):722-731. PMID: 35043946; PMCID: PMC9086756.

  • Leppig KA, Kulchak Rahm A, Appelbaum P, Aufox S, Bland ST, Buchanan A, Christensen KD, Chung WK, Clayton EW, Crosslin D, Denny J, DeVange S, Gordon A, Green RC, Hakonarson H, Harr MH, Henrikson N, Hoell C, Holm IA, Kullo IJ, Jarvik GP, Lammers PE, Larson EB, Lindor NM, Marasa M, Myers MF, Perez E, Peterson JF, Pratap S, Prows CA, Ralston JD, Rasouly HM, Roden DM, Sharp RR, Singh R, Shaibi G, Smith ME, Sturm A, Thiese HA, Van Driest SL, Williams J, Williams MS, Wynn J, Blout Zawatsky CL, Wiesner GL. The reckoning: The return of genomic results to 1444 participants across the eMERGE3 Network. Genet Med. 2022 May;24(5):1130-1138. Epub 2022 Feb 23. PMID: 35216901.

  • Degeling K, IJzerman MJ, Groothuis-Oudshoorn CGM, Franken MD, Koopman M, Clements MS, Koffijberg H. Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer. Value Health. 2022 Jan;25(1):104-115. Epub 2021 Sep 8. PMID: 35031089.

  • Tsiachristas A, Vallance G, Koleva-Kolarova R, Taylor H, Solomons L, Rizzo G, Chaytor C, Miah J, Wordsworth S, Hassan AB. Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients. BMC Cancer. 2022 Apr 26;22(1):458. PMID: 35473510; PMCID: PMC9044697.

  • Vass C, Boeri M, Karim S, Marshall D, Craig B, Ho KA, Mott D, Ngorsuraches S, Badawy SM, Mühlbacher A, Gonzalez JM, Heidenreich S. Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report. Value Health. 2022 May;25(5):685-694. PMID: 35500943.

  • Buchanan J, Hill M, Vass CM, Hammond J, Riedijk S, Klapwijk JE, Harding E, Lou S, Vogel I, Hui L, Ingvoldstad-Malmgren C, Soller MJ, Ormond KE, Choolani M, Zheng Q, Chitty LS, Lewis C. Factor's that impact on women's decision-making around prenatal genomic tests: An international discrete choice survey. Prenat Diagn. 2022 Apr 27. Epub ahead of print. PMID: 35476801.

  • Shickh S, Oldfield LE, Clausen M, Mighton C, Sebastian A, Calvo A, Baxter NN, Dawson L, Penney LS, Foulkes W, Basik M, Sun S, Schrader KA, Regier DA, Karsan A, Pollett A, Pugh TJ, Kim RH, Bombard Y; CHARM Consortium. "Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management. Oncologist. 2022 Apr 6:oyac039. Epub ahead of print. PMID: 35385106.

  • Xie X, Tiggelaar S, Guo J, Wang M, Vandersluis S, Ungar WJ. Developing Economic Models for Assessing the Cost-Effectiveness of Multiple Diagnostic Tests: Methods and Applications. Med Decis Making. 2022 Apr 3:272989X221089268. Epub ahead of print. PMID: 35373634.

  • Koleva-Kolarova R, Buchanan J, Vellekoop H, Huygens S, Versteegh M, Mölken MR, Szilberhorn L, Zelei T, Nagy B, Wordsworth S, Tsiachristas A; HEcoPerMed Consortium. Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options. Appl Health Econ Health Policy. 2022 Apr 4. Epub ahead of print. PMID: 35368231.

  • Lavelle TA, Feng X, Keisler M, Cohen JT, Neumann PJ, Prichard D, Schroeder BE, Salyakina D, Espinal PS, Weidner SB, Maron JL. Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions. Genet Med. 2022 Apr 8:S1098-3600(22)00682-7. Epub ahead of print. PMID: 35396982.

  • McPhail M, McCabe C, Regier DA, Bubela T. The Importance of and Challenges with Adopting Life-Cycle Regulation and Reimbursement in Canada. Healthc Policy. 2022 Feb;17(3):81-90. PMID: 35319446; PMCID: PMC8935925.

  • Pataky R, Tran DA, Coronado A, Alvi R, Boehm D, Regier DA, Peacock S. Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysis. CMAJ Open. 2018 Jul 27;6(3):E292-E299. PMID: 30054297; PMCID: PMC6182106.

  • van de Ven M, IJzerman M, Retèl V, van Harten W, Koffijberg H. Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer. BMC Med Res Methodol. 2022 Mar 27;22(1):83. PMID: 35350994; PMCID: PMC8962015.

  • Weymann D, Pollard S, Chan B, Titmuss E, Bohm A, Laskin J, Jones SJM, Pleasance E, Nelson J, Fok A, Lim H, Karsan A, Renouf DJ, Schrader KA, Sun S, Yip S, Schaeffer DF, Marra MA, Regier DA. Clinical and cost outcomes following genomics-informed treatment for advanced cancers. Cancer Med. 2021 Aug;10(15):5131-5140. PMID: 34152087; PMCID: PMC8335838.

  • Deverka PA, Douglas MP, Phillips KA. Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access. Health Aff (Millwood). 2022 Mar;41(3):383-389. PMID: 35254936.

  • Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian A, Phillips KA. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. J Genet Couns. 2022 Feb;31(1):130-139. PMID: 34231930; PMCID: PMC8893352.

  • Brunette CA, Dong OM, Vassy JL, Danowski ME, Alexander N, Antwi AA, Christensen KD. A Cost-Consequence Analysis of Preemptive SLCO1B1 Testing for Statin Myopathy Risk Compared to Usual Care. J Pers Med. 2021 Oct 31;11(11):1123. PMID: 34834475; PMCID: PMC8624003.

  • Morrell L, Buchanan J, Rees S, Barker RW, Wordsworth S. What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK. Pharmacoeconomics. 2021 Dec;39(12):1443-1454. Epub 2021 Aug 19. PMID: 34409564; PMCID: PMC8599241.

  • Vellekoop H, Versteegh M, Huygens S, Corro Ramos I, Szilberhorn L, Zelei T, Nagy B, Tsiachristas A, Koleva-Kolarova R, Wordsworth S, Rutten-van Mölken M; HEcoPerMed consortium. The Net Benefit of Personalized Medicine: A Systematic Literature Review and Regression Analysis. Value Health. 2022 Mar 2:S1098-3015(22)00056-0. Epub ahead of print. PMID: 35248467.

  • Halley MC, Smith HS, Ashley EA, Goldenberg AJ, Tabor HK. A call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United States. Nat Genet. 2022 Mar;54(3):219-222. PMID: 35256804.

  • Jansen JP, Trikalinos TA, Phillips KA. Assessments of the Value of New Interventions Should Include Health Equity Impact. Pharmacoeconomics. 2022 Mar 3:1–7.  Epub ahead of print. PMID: 35237944; PMCID: PMC8890816.

  • Jegathisawaran J, Tsiplova K, Hayeems RZ, Marshall CR, Stavropoulos DJ, Pereira SL, Thiruvahindrapuram B, Liston E, Reuter MS, Manshaei R, Cohn I, Jobling R, Kim RH, Mital S, Ungar WJ. Trio genome sequencing for developmental delay and pediatric heart conditions: A comparative microcost analysis. Genet Med. 2022 Feb 23:S1098-3600(22)00036-3. Epub ahead of print. PMID: 35219592.

  • Pollard S, Weymann D, Chan B, Ehman M, Wordsworth S, Buchanan J, Hanna TP, Ho C, Lim HJ, Lorgelly PK, Raymakers AJN, McCabe C, Regier DA. Defining a Core Data Set for the Economic Evaluation of Precision Oncology. Value Health. 2022 Feb 23:S1098-3015(22)00055-9. Epub ahead of print. PMID: 35216902.

  • Leppig KA, Kulchak Rahm A, Appelbaum P, Aufox S, Bland ST, Buchanan A, Christensen KD, Chung WK, Clayton EW, Crosslin D, Denny J, DeVange S, Gordon A, Green RC, Hakonarson H, Harr MH, Henrikson N, Hoell C, Holm IA, Kullo IJ, Jarvik GP, Lammers PE, Larson EB, Lindor NM, Marasa M, Myers MF, Perez E, Peterson JF, Pratap S, Prows CA, Ralston JD, Rasouly HM, Roden DM, Sharp RR, Singh R, Shaibi G, Smith ME, Sturm A, Thiese HA, Van Driest SL, Williams J, Williams MS, Wynn J, Blout Zawatsky CL, Wiesner GL. The reckoning: The return of genomic results to 1444 participants across the eMERGE3 Network. Genet Med. 2022 Feb 22:S1098-3600(22)00031-4. PMID: 35216901.

  • Cernat A, Bashir NS, Ungar WJ. Considerations for developing regulations for direct-to-consumer genetic testing: a scoping review using the 3-I framework. J Community Genet. 2022 Feb 16. Epub ahead of print. PMID: 35171498.

  • Vu M, Degeling K, Thompson ER, Blombery P, Westerman D, IJzerman MJ. Health economic evidence for the use of molecular biomarker tests in hematological malignancies: a systematic review. Eur J Haematol. 2022 Feb 14. Epub ahead of print. PMID: 35158410.

  • Goranitis I, Wu Y, Lunke S, White SM, Tan TY, Yeung A, Hunter MF, Martyn M, Gaff C, Stark Z. Is faster better? An economic evaluation of rapid and ultra-rapid genomic testing in critically ill infants and children. Genet Med. 2022 Feb 15:S1098-3600(22)00029-6. Epub ahead of print. PMID: 35181209.

  • Hajek C, Hutchinson AM, Galbraith LN, Green RC, Murray MF, Petry N, Preys CL, Zawatsky CLB, Zoltick ES, Christensen KD; Imagenetics METRICS Team. Improved provider preparedness through an 8-part genetics and genomic education program. Genet Med. 2022 Jan;24(1):214-224.  Epub 2021 Nov 30. PMID: 34906462.

  • Ten Ham RMT, Walker SM, Soares MO, Frederix GWJ, Leebeek FWG, Fischer K, Coppens M, Palmer SJ. Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A. Hemasphere. 2022 Jan 28;6(2):e679. Erratum in: Hemasphere. 2022 Feb 15;6(3):e698. PMID: 35141470; PMCID: PMC8820916.

  • Zhang J, IJzerman MJ, Oberoi J, Karnchanachari N, Bergin RJ, Franchini F, Druce P, Wang X, Emery JD. Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes. Lung Cancer. 2022 Jan 25;166:27-39. Epub ahead of print. PMID: 35152171.

  • de Rouw N, de Boer M, Boosman RJ, van den Heuvel MM, Burger DM, Lieverse JE, Derijks HJ, Frederix GWJ, Ter Heine R. The pharmacoeconomic benefits of pemetrexed dose individualization in lung cancer patients. Clin Pharmacol Ther. 2022 Jan 20. Epub ahead of print. PMID: 35048355.

  • Kunst N, Stout NK, O'Brien G, Christensen KD, McMahon PM, Wu AC, Diller L, Yeh JM. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. J Natl Cancer Inst. 2022 Jan 19:djac013. Epub ahead of print. PMID: 35043946.

  • Hammond J, Klapwijk JE, Riedijk S, Lou S, Ormond KE, Vogel I, Hui L, Sziepe EJ, Buchanan J, Ingvoldstad-Malmgren C, Soller MJ, Harding E, Hill M, Lewis C. Assessing women's preferences towards tests that may reveal uncertain results from prenatal genomic testing: Development of attributes for a discrete choice experiment, using a mixed-methods design. PLoS One. 2022 Jan 28;17(1):e0261898. PMID: 35089945.

  • Hayeems RZ, Michaels-Igbokwe C, Venkataramanan V, Hartley T, Acker M, Gillespie M, Ungar WJ, Mendoza-Londona R, Bernier FP, Boycott KM, Marshall DA. The complexity of diagnosing rare disease: An organizing framework for outcomes research and health economics based on real-world evidence. Genet Med. 2021 Dec 3:S1098-3600(21)05383-1. PMID: 34906497.

  • Simons M, Van De Ven M, Coupé V, Joore M, IJzerman M, Koffijberg E, Frederix G, Uyl-De Groot C, Cuppen E, Van Harten W, Retèl V. Early technology assessment of using whole genome sequencing in personalized oncology. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):343-351. PMID: 33910430.

  • Pollard S, Weymann D, Dunne J, Mayanloo F, Buckell J, Buchanan J, Wordsworth S, Friedman JM, Stockler-Ipsiroglu S, Dragojlovic N, Elliott AM, Harrison M, Lynd LD, Regier DA. Toward the diagnosis of rare childhood genetic diseases: what do parents value most? Eur J Hum Genet. 2021 Oct;29(10):1491-1501. Erratum in: Eur J Hum Genet. 2021 Jun 18;: PMID: 33903739; PMCID: PMC8484431.

  • Hayeems RZ, Luca S, Ungar WJ, Venkataramanan V, Tsiplova K, Bashir NS, Costain G, Inglese C, McNiven V, Quercia N, Shugar A, Yoon G, Cytrynbaum C, Dupuis L, Shao Z, Hewson S, Shuman C, Aul R, Liston E, Babul-Hirji R, Bushby A, Pullenayegum E, Chad L, Meyn MS. The Clinician-reported Genetic testing Utility InDEx (C-GUIDE): Preliminary evidence of validity and reliability. Genet Med. 2021 Nov 16:S1098-3600(21)05355-7. doi: 10.1016/j.gim.2021.10.005. Epub ahead of print. PMID: 34906486.

  • Pollard S, Dunne J, Costa S, Regier DA. Stakeholder Perspectives on Navigating Evidentiary and Decision Uncertainty in Precision Oncology. J Pers Med. 2022 Jan 1;12(1):22. doi: 10.3390/jpm12010022. PMID: 35055337.

  • Manolio TA, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Goldrich M, Jarvik GP, Mensah GA, Ramos EM, Relling MV, Roden DM, Rowley R, Williams MS, Green ED. Genomic medicine year in review: 2021. Am J Hum Genet. 2021 Dec 2;108(12):2210-2214. PMID: 34861172.

  • Elsink K, Huibers MMH, Hollink IHIM, Simons A, Zonneveld-Huijssoon E, van der Veken LT, Leavis HL, Henriet SSV, van Deuren M, van de Veerdonk FL, Potjewijd J, Berghuis D, Dalm VASH, Vermont CL, van de Ven AAJM, Lambeck AJA, Abbott KM, van Hagen PM, de Bree GJ, Kuijpers TW, Frederix GWJ, van Gijn ME, van Montfrans JM; Genetics First for Primary Immunodeficiency Disorders Consortium. Implementation of Early Next-Generation Sequencing for Inborn Errors of Immunity: A Prospective Observational Cohort Study of Diagnostic Yield and Clinical Implications in Dutch Genome Diagnostic Centers. Front Immunol. 2021 Dec 21;12:780134. PMID: 34992599; PMCID: PMC8724043.

  • Phillips KA, Trosman JR, Douglas MP, Gelb BD, Ferket BS, Hindorff LA, Slavotinek AM, Berg JS, Russell HV, Devine B, Greve V, Smith HS. US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER). Genet Med. 2022 Jan;24(1):238-244. Epub 2021 Nov 30. PMID: 34906461.

  • Gupta A, Cafazzo JA, IJzerman MJ, Swart JF, Vastert S, Wulffraat NM, Benseler S, Marshall D, Yeung R, Twilt M. Genomic Health Literacy Interventions in Pediatrics: Scoping Review. J Med Internet Res. 2021 Dec 24;23(12):e26684. PMID: 34951592.

  • Pearson SA, Pratt N, de Oliveira Costa J, Zoega H, Laba TL, Etherton-Beer C, Sanfilippo FM, Morgan A, Kalisch Ellett L, Bruno C, Kelty E, IJzerman M, Preen DB, Vajdic CM, Henry D. Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future. Int J Environ Res Public Health. 2021 Dec 18;18(24):13345. PMID: 34948955.

  • Yuen T, Carter MT, Szatmari P, Ungar WJ. Cost-effectiveness of Genome and Exome Sequencing in Children Diagnosed with Autism Spectrum Disorder. Appl Health Econ Health Policy. 2018 Aug;16(4):481-493. PMID: 29651777.

  • Hayeems RZ, Michaels-Igbokwe C, Venkataramanan V, Hartley T, Acker M, Gillespie M, Ungar WJ, Mendoza-Londona R, Bernier FP, Boycott KM, Marshall DA. The complexity of diagnosing rare disease: An organizing framework for outcomes research and health economics based on real-world evidence. Genet Med. 2021 Dec 3. Epub ahead of print.

  • Weymann D, Laskin J, Jones SJM, Roscoe R, Lim HJ, Renouf DJ, Schrader KA, Sun S, Yip S, Marra MA, Regier DA. Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care. J Community Genet. 2021 Nov 29:1–16. Epub ahead of print. PMID: 34843087.

  • Wynn J, Milo Rasouly H, Vasquez-Loarte T, Saami AM, Weiss R, Ziniel SI, Appelbaum PS, Wright Clayton E, Christensen KD, Fasel D, Green RC, Hain HS, Harr M, Hoell C, Kullo IJ, Leppig KA, Myers MF, Pacyna JE, Perez EF, Prows CA, Kulchak Rahm A, Campbell-Salome G, Sharp RR, Smith ME, Wiesner GL, Williams JL, Blout Zawatsky CL, Gharavi AG, Chung WK, Holm IA. Do research participants share genomic screening results with family members? J Genet Couns. 2021 Oct 19. Epub ahead of print. PMID: 34665896.

  • Blout Zawatsky CL, Shah N, Machini K, Perez E, Christensen KD, Zouk H, Steeves M, Koch C, Uveges M, Shea J, Gold N, Krier J, Boutin N, Mahanta L, Rehm HL, Weiss ST, Karlson EW, Smoller JW, Lebo MS, Green RC. Returning actionable genomic results in a research biobank: Analytic validity, clinical implementation, and resource utilization. Am J Hum Genet. 2021 Nov 3:S0002-9297(21)00382-7. Epub ahead of print. PMID: 34752750.

  • Schroeder BE, Gonzaludo N, Everson K, Than KS, Sullivan J, Taft RJ, Belmont JW. The diagnostic trajectory of infants and children with clinical features of genetic disease. NPJ Genom Med. 2021 Nov 22;6(1):98. PMID: 34811359; PMCID: PMC8609026.

  • Douglas MP, Lin GA, Trosman JR, Phillips KA. Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants. J Community Genet. 2021 Nov 6. Epub ahead of print. PMID: 34743282.

  • Jayasinghe K., Wu Y., Stark Z., Kerr P.G., Mallett A.J., Gaff C., Martyn M., Goranitis I., Quinlan C. Cost-Effectiveness of Targeted Exome Analysis as a Diagnostic Test in Glomerular Diseases. Kidney Intl. Rep. 2021 6:11 (2850-2861).

  • 100,000 Genomes Project Pilot Investigators (including Wordsworth S and Buchanan J). 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report. N Engl J Med. 2021 Nov 11;385(20):1868-1880. doi: 10.1056/NEJMoa2035790. PMID: 34758253.

  • Smith HS, Morain SR, Robinson JO, Canfield I, Malek J, Rubanovich CK, Bloss CS, Ackerman SL, Biesecker B, Brothers KB, Goytia CN, Horowitz CR, Knight SJ, Koenig B, Kraft SA, Outram S, Rini C, Shipman KJ, Waltz M, Wilfond B, McGuire AL. Perceived Utility of Genomic Sequencing: Qualitative Analysis and Synthesis of a Conceptual Model to Inform Patient-Centered Instrument Development. Patient. 2021 Oct 18. doi: 10.1007/s40271-021-00558-4. Epub ahead of print. PMID: 34658003.

  • Meng Y, Clarke PM, Goranitis I. The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions. Pharmacoeconomics. 2021 Oct 21. doi: 10.1007/s40273-021-01103-9. Epub ahead of print. PMID: 34671943.

  • O'Brien G, Christensen KD, Sullivan HK, Stout NK, Diller L, Yeh JM, Wu AC. Estimated Cost-effectiveness of Genetic Testing in Siblings of Newborns With Cancer Susceptibility Gene Variants. JAMA Netw Open. 2021 Oct 1;4(10):e2129742. doi: 10.1001/jamanetworkopen.2021.29742. PMID: 34661666.

  • Witteman HO, Ndjaboue R, Vaisson G, Dansokho SC, Arnold B, Bridges JFP, Comeau S, Fagerlin A, Gavaruzzi T, Marcoux M, Pieterse A, Pignone M, Provencher T, Racine C, Regier D, Rochefort-Brihay C, Thokala P, Weernink M, White DB, Wills CE, Jansen J. Clarifying Values: An Updated and Expanded Systematic Review and Meta-Analysis. Med Decis Making. 2021 Oct;41(7):801-820. doi: 10.1177/0272989X211037946. PMID: 34565196; PMCID: PMC8482297.

  • Chan KKW, Cheung MC, Regier DA, Hay A, Louie AV, Cheung WY, Tarride JE, Udayakumar S, Mittmann N. The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group. Curr Oncol. 2021 Sep 21;28(5):3649-3658. doi: 10.3390/curroncol28050311. PMID: 34590616; PMCID: PMC8482104.

  • Mighton C, Clausen M, Sebastian A, Muir SM, Shickh S, Baxter NN, Scheer A, Glogowski E, Schrader KA, Thorpe KE, Kim THM, Lerner-Ellis J, Kim RH, Regier DA, Bayoumi AM, Bombard Y. Patient and public preferences for being recontacted with updated genomic results: a mixed methods study. Hum Genet. 2021 Sep 18. doi: 10.1007/s00439-021-02366-0. Epub ahead of print. PMID: 34537903.

  • Weymann D, Laskin J, Jones SJM, Lim H, Renouf DJ, Roscoe R, Schrader KA, Sun S, Yip S, Marra MA, Regier DA. Matching methods in precision oncology: An introduction and illustrative example. Mol Genet Genomic Med. 2021 Jan;9(1):e1554. doi: 10.1002/mgg3.1554. Epub 2020 Nov 25. PMID: 33237632; PMCID: PMC7963415.

  • Morrell L, Buchanan J, Rees S, Barker RW, Wordsworth S. What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK. Pharmacoeconomics. 2021 Aug 19. doi: 10.1007/s40273-021-01067-w. Epub ahead of print. PMID: 34409564.

  • IJzerman MJ. Cost of colorectal cancer care: sufficient to inform cancer policy? Lancet Gastroenterol Hepatol. 2021 Sep;6(9):679-680. doi: 10.1016/S2468-1253(21)00177-1. Epub 2021 Jul 28. PMID: 34329625.

  • Christensen KD, Schonman EF, Robinson JO, Roberts JS, Diamond PM, Lee KB, Green RC, McGuire AL. Behavioral and psychological impact of genome sequencing: a pilot randomized trial of primary care and cardiology patients. NPJ Genom Med. 2021 Aug 24;6(1):72. doi: 10.1038/s41525-021-00236-2. PMID: 34429410.

  • Cernat A, Hayeems RZ, Ungar WJ. Cascade health service use in family members following genetic testing in children: a scoping literature review. Eur J Hum Genet. 2021 Aug 26. doi: 10.1038/s41431-021-00952-4. Epub ahead of print. PMID: 34446836.

  • Gonzalez Sepulveda JM, Johnson FR, Marshall DA. Incomplete information and irrelevant attributes in stated-preference values for health interventions. Health Econ. 2021 Jul 30. doi: 10.1002/hec.4406. Epub ahead of print. PMID: 34331384.

  • Degeling K., Pereira-Salgado A., Corcoran N.M., Boutros P.C., Kuhn P., IJzerman M.J. Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review. European Urology Open Science. 2021;27:77-87.

  • IJzerman MJ, de Boer J, Azad A, Degeling K, Geoghegan J, Hewitt C, Hollande F, Lee B, To YH, Tothill RW, Wright G, Tie J, Dawson SJ. Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. Diagnostics (Basel). 2021 Jan 11;11(1):103. PMID: 33440749.

  • Wu Y, Balasubramaniam S, Rius R, Thorburn DR, Christodoulou J, Goranitis I. Genomic sequencing for the diagnosis of childhood mitochondrial disorders: a health economic evaluation. Eur J Hum Genet. 2021 Jun 8. PMID: 34099885.

  • To YH, Degeling K, Kosmider S, Wong R, Lee M, Dunn C, Gard G, Jalali A, Wong V, IJzerman M, Gibbs P, Tie J. Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer. Pharmacoeconomics. 2021 Jun 5. PMID: 34089503.

  • Weymann D, Pollard S, Chan B, Titmuss E, Bohm A, Laskin J, Jones SJM, Pleasance E, Nelson J, Fok A, Lim H, Karsan A, Renouf DJ, Schrader KA, Sun S, Yip S, Schaeffer DF, Marra MA, Regier DA. Clinical and cost outcomes following genomics-informed treatment for advanced cancers. Cancer Med. 2021 Jun 21. PMID: 34152087.

  • Downie L, Amor DJ, Halliday J, Lewis S, Martyn M, Goranitis I. Exome Sequencing for Isolated Congenital Hearing Loss: A Cost-Effectiveness Analysis. Laryngoscope. 2020 Dec 31. doi: 10.1002/lary.29356. Epub ahead of print. PMID: 33382469.

  • Vellekoop H, Huygens S, Versteegh M, Szilberhorn L, Zelei T, Nagy B, Koleva-Kolarova R, Tsiachristas A, Wordsworth S, Rutten-van Mölken M; HEcoPerMed Consortium. Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. Pharmacoeconomics. 2021 Apr 16. doi: 10.1007/s40273-021-01010-z. Epub ahead of print. PMID: 33860928.

  • Smith HS, McGuire AL, Wittenberg E, Lavelle TA. Family-level impact of genetic testing: integrating health economics and ethical, legal, and social implications. Per Med. 2021 May;18(3):209-212. doi: 10.2217/pme-2021-0016. Epub 2021 Mar 17. PMID: 33728981.

  • Pasmans CTB, Tops BBJ, Steeghs EMP, Coupé VMH, Grünberg K, de Jong EK, Schuuring EMD, Willems SM, Ligtenberg MJL, Retèl VP, van Snellenberg H, de Bruijn E, Cuppen E, Frederix GWJ. Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing. Expert Rev Pharmacoecon Outcomes Res. 2021 May 6:1-11. doi: 10.1080/14737167.2021.1917385. Epub ahead of print. PMID: 33852815.

  • van de Ven M, Simons MJHG, Koffijberg H, Joore MA, IJzerman MJ, Retèl VP, van Harten WH. Whole genome sequencing in oncology: using scenario drafting to explore future developments. BMC Cancer. 2021 May 1;21(1):488. doi: 10.1186/s12885-021-08214-8. PMID: 33933021; PMCID: PMC8088550.

  • Simons M, van de Ven M, Coupé V, Joore M, IJzerman M, Koffijberg E, Frederix G, Uyl-De Groot C, Cuppen E, van Harten W, Retèl V. Early technology assessment of using whole genome sequencing in personalised oncology. Expert Rev Pharmacoecon Outcomes Res. 2021 Apr 29. doi: 10.1080/14737167.2021.1917386. Epub ahead of print. PMID: 33910430.